A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.
Advanced Endometrial Cancer
DRUG: TQB2450|DRUG: Anlotinib
Overall response rate (ORR) evaluated by Independent Review Committee(IRC), ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on IRC., up to 12 months
Overall response rate (ORR) evaluated by investigator, ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator., up to 12 months|Disease control rate (DCR), Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 12 months|Duration of response (DOR), The time when the participants first achieved complete or partial remission to disease progression., up to 12 months|Progression free survival(PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 12 months|Overall survival(OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 18 months|DOR rate (≥ 6 months), The percentage of participants achieved complete or partial remission ≥ 6 months., up to 6 months
This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.